NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

Not to mention DCVax-Direct which has patent protection on the latest improvement/version until about 2036 perhaps 2037.

NWBO ran a P1 trial with Direct 10 years ago. It had an efficacy endpoint of ORR, and that showed 0 ORR. Since then it has been on the shelf right next to DCVax-Prostate that last was in trials in a previous millennium.

DCVax-l is protected by more than orphan status exclusive use (10 years from first approval)

You are absolutely correct that if the trial can garner an approval then NWBO "owns" the ATL-DC GBM space. The question is why BP is not looking at other indications.

It is also protected by exclusive data use. Nobody else can use the phase iii trial data (long term safety and efficacy) to support any attempts at biosimilars for about a decade.

For other indications than GBM, BP could easily have started trials years ago and have a lead on NWBO. They did not. Wonder why?